AURORA CANNABIS INC

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: -$10M FCF in FY27 reflecting Canadian medical-cannabis pricing cuts effective April 2026 per management guidance, turning to $5M in FY28 and growing to $60M by FY36 as medical and international export volumes and margins expand; 14% discount rate; 2.5% terminal growth; plus $164.7M of net cash (the company is debt-free); 64.86M shares outstanding.

Reasoning: Aurora is debt-free with a large net-cash position and record FY26 adjusted EBITDA of $53.8M (+32% y/y), but management guided FY27 revenue and adjusted EBITDA to decline on regulatory pricing pressure, so the model bakes in a near-term dip before resuming modest medical-cannabis-led growth; the 14% discount rate and below-market growth assumptions reflect the cannabis sector's history of value destruction and regulatory volatility.